RxDoctor Payments Data

Felicia Tillman, MD

Obstetrics & Gynecology · Santa Fe, NMNPI 1356343149

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.1% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $524 and has fallen 63.7% since, to $190 in 2025.

$2,096in general payments, 2019–2025

Across 97 payments — averaging $21.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$354
  • Exeltis, USA Inc.$199
  • Astellas Pharma US Inc$165
  • Merck$162
  • Gynesonics, Inc.$120
  • Pfizer$118
  • plus $978 from 25 others
$155,569in research payments, 2019–2025

Across 38 payments — averaging $4093.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Mylan Inc.$156K

What the payments were for

  • Food & beverage$2,05698%
  • Education$402%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,096 in reported general payments places this provider in the 85th percentile of 181 obstetrics & gynecology providers in New Mexico.

See all obstetrics & gynecology providers in New Mexico

Medicare billing

Part B allowed, 2024
$9,955
Medicare patients
56
Services billed
96

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol15$830

Paid to pharmacies, not to this prescriber.

Other obstetrics & gynecology in Santa Fe

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →